Cancer Immunotherapy Market Size, Share, By Product Type (Monoclonal Antibodies, Immunomodulators, Checkpoint Inhibitors, Adoptive Cell Therapy, and Others), Cancer Type (Lung Cancer, Colorectal Cancer, Melanoma, Breast Cancer, Head & Neck Cancer, Prostate Cancer, and Others), End-User (Hospitals, Cancer Research Centers, and Others), and Region - Trends, Analysis and Forecast till 2034

• The cancer immunotherapy market size is projected to reach USD 530.2 billion by 2034.
• The market was valued at USD 158.5 billion in 2024.
• The market is expected to expand at a CAGR of 14.2% during the forecast period.

Cancer immunotherapy represents a new and bright approach to cancer treatment, whereby one's immune system is manipulated to battle malignant cells. This new approach for treating cancers works by stimulating or enhancing natural defense mechanisms of the immune system itself to either engender or enhance its ability to recognize and attack the tumor cells. The increasing research in cancer immunotherapy is expected to propel market growth during the forecast period.

Key Takeaways:

• North America holds the largest share in the market owing to the rising incidences of cancer in the region.  
• Asia Pacific is expected to witness fast growth during the forecast period. The region’s growth is attributed to the improving healthcare infrastructure in the region.

Increasing Cancer Prevalence and Rising Efficacy of Immunotherapy to Boost Market Growth

• The total burden of cancer is rising across the globe, and more patients are diagnosed with various forms of it. This has resulted in a vast market for immunotherapy treatment. Because the incidence of cancers is continually increasing, the demand for its therapies, such as immunotherapy, is also rising.

• Research innovations in this area have led to the creation of highly effective treatments, where cells causing cancer can be targeted for elimination by immunotherapy. As a result, a tremendous amount of interest and investment in treatment given challenging cancers, respectively, has attracted to this sphere of therapy. The continual results it has portrayed from its clinical trials mean that there is the potential for further growth in the adoption of immunotherapy.

• Investments in cancer immunotherapy research are essential for new treatment approaches. An increasing understanding of the immune system and its interaction with cancer has found novel targets and therapeutic strategies. This pipeline of immunotherapies is thus growing in response to the growing research.

Restraints:

High Cost of Treatment to Impede Market Growth

• One major drawback of this therapy, however, is its high cost, which limits its wide adoption. Immunotherapy is costly, as most of these treatments are complex and demand expert care. Due to the cost aspect, very rare grounds are covered, especially patient access, in areas where health coverage is quite low.

Opportunities:

Expanding Treatment Indications and Combination Therapies to Boost Market Expansion

• The expansion of cancer immunotherapy to other areas of cancer is also seen as an important opportunity. While there has been massive success in immunotherapy for some types of cancer, there is huge scope for treatments for other solid tumors and hematological malignancies. The identification of new immune targets and the development of innovative therapies could further expand the market.
• Potentiating immunotherapy for better clinical response with a combination of other treatment modalities, such as chemotherapy, radiation, or targeted therapies, would be a promising approach. Combining these approaches optimally would yield synergistic effects, improving patient outcomes and outsmarting acquired treatment resistances. Such a trial-combining strategy for improved therapeutic opportunities has a big scope for market interest.

The cancer immunotherapy market is segmented into product type, cancer type, end-user, and region.

Product Type:

By product type, the market is classified into monoclonal antibodies, immunomodulators, checkpoint inhibitors, adoptive cell therapy, and others. The monoclonal antibodies segment is expected to lead the market during the forecast period as these antibodies bind with particular proteins on a cancer cell’s surface.

Cancer Type:

Based on cancer type, the market is divided into lung cancer, colorectal cancer, melanoma, breast cancer, head & neck cancer, prostate cancer, and others. Lung cancer is the most dominant segment in the market as it is one of the most common cancers that is being treated with immunotherapy.

End-User Insights:

On the basis of end-user, the market is classified into hospitals, cancer research centers, and others. The hospitals segment is holding the largest cancer immunotherapy market share owing to the increased infrastructure to manage the adverse effects of these therapies along with the complications to care for cancer patients.

Regional Insights:

Geographically, the cancer immunotherapy market is analyzed across North America, Asia Pacific, Europe, Latin America, and the Middle East & Africa.

• North America: North America dominates the largest market share, especially in the US, due to its well-established healthcare infrastructure, acceptance and investment in new technologies, and high funding for R&D. Hence, a high incidence of cancer in the region, coupled with the presence of major pharmaceutical companies, continues to drive growth in immunotherapies.
• Asia Pacific: The region of Asia Pacific is also presenting fast growth in the cancer immunotherapy market, driven by an increase in cancer incidence, improving healthcare infrastructure, and increasing access to newer treatments. Countries such as China, Japan, and India are among the recipients of investments in cancer research, thus expanding the market scope.

Cancer Immunotherapy Market Report Scope:

Segmentation:

By Product Type:

• Monoclonal Antibodies
• Immunomodulators
• Checkpoint Inhibitors
• Adoptive Cell Therapy
• Others

By Cancer Type:

• Lung Cancer
• Colorectal Cancer
• Melanoma
• Breast Cancer
• Head & Neck Cancer
• Prostate Cancer
• Others

By End-User:

• Hospitals
• Cancer Research Centers
• Others

By Region:

North America

• U.S.
• Canada

Europe

• Germany
• U.K.
• France
• Russia
• Italy
• Rest of Europe

Asia Pacific

• China
• India
• Japan
• South Korea
• Rest of Asia Pacific

Latin America

• Brazil
• Mexico
• Rest of Latin America

Middle East & Africa

• GCC
• Israel
• South Africa
• Rest of Middle East & Africa

The key players operating in the cancer immunotherapy market include Amgen, Inc., AstraZeneca, Plc, Bristol-Myers Squibb Company, and Pfizer, Inc., among others. These key players are conducting different trails to enhance their product portfolio among their competitors.

List of Key Players in the Market:

• Amgen, Inc.
• AstraZeneca, PLC
• Bayer AG
• Bristol-Myers Squibb Company
• Eli Lily And Company
• F. Hoffmann-La Roche, Ltd.
• Pfizer, Inc.
• Johnson & Johnson Services, Inc
• Merck & Co., Inc
• Novartis AG
• Immunocore, Ltd.

                     To Access More Companies, Download Free Sample PDF

• In June 2024, a new phase 2 research started to examine a triple medication combination for pancreatic cancer. The University of Glasgow and the NHS Greater Glasgow and Clyde have initiated a mid-stage trial to test a new drug combination as a first-line treatment for patients with metastatic pancreatic cancer. The phase 2 PRIMUS-006 study, part of the Precision-Panc Platform, will evaluate Eli Lilly and Genentech's Gemzar (gemcitabine) in combination with Merck & Co's Keytruda (pembrolizumab), known as MSD outside the U.S. and Canada, and Immodulon Therapeutics' investigational IMM-101 in metastatic pancreatic ductal adenocarcinoma (PDAC).
• In April 2024, Hope beckons as the first homegrown cell therapy for cancer treatment is announced. President Droupadi Murmu introduced India's first indigenously developed CAR T-cell therapy for cancer treatment, calling it a "breakthrough" that will give humanity new hope in the fight against the disease. NexCAR19 CAR T-cell therapy is the country's first 'Made in India' cell therapy, and it will considerably reduce cancer treatment costs. This gene-based therapy, developed by the Indian Institute of Technology (IIT) Bombay and the Tata Memorial Centre, aims to cure several types of cancer.

More Related Reports

Head and Neck Cancer Market
HER2-Positive Breast Cancer Market
Small Cell Lung Cancer Market
Lung Cancer Market
Bispecific Antibodies Market